CEO Jeff Galvin Addresses Congress on the Biotechnology Investment Tax Credit

By AGT | Mar 8, 2016
Filed Under:

Jeff Galvin, CEO of American Gene Technologies provided testimony in a Senate Hearing on March 8, 2016 in support of Maryland’s Biotechnology Investment Incentive Tax Credit. His goal? To alter the definition of “qualified Maryland biotechnology company” so that an active business may claim the biotechnology tax credit – empowering gene therapy startups in the state of Maryland.

American Gene Technologies Welcomes Visionary Leader to Board of Directors

By AGT | Jan 27, 2016
Filed Under:

ROCKVILLE, Md. (January 27, 2016) – American Gene Technologies International, Inc. (AGT) today announced the appointment of Stuart B. Baker, MD to its board of directors. The latest addition to the emerging biotech’s roster of world-renowned experts comes on the heels of the addition of David C. Pauza, Ph.D., who was named Chief Science Officer at AGT earlier this month…. [Read More]

Obama’s Anti-Cancer Moonshot Will Need More Than Research

By AGT | Jan 13, 2016
Filed Under:

On January 13, 2016, American Gene CEO, Jeff Galvin was asked to weigh in on Vice President Biden’s “moonshot to cure cancer”.

American Gene Technologies announces Dr. David Pauza as Chief Science Officer

By AGT | Jan 8, 2016
Filed Under:

GLOBAL EXPERT IN VIROLOGY AND IMMUNOLOGY TO LEAD GROUNDBREAKING GENETIC DRUG DEVELOPMENT ROCKVILLE, Md. (January 8, 2016) – American Gene Technologies (AGT) today announced that Dr. David Pauza will serve as Chief Science Officer. Pauza brings a global reputation as a leading expert in virology and immunology to AGT, where he will lead AGT’s groundbreaking genetic drug development. “The gravity of our pursuit… [Read More]

AGT Receives NIH Grant for FD Research

By AGT | Aug 10, 2015
Filed Under:

NIH Grant to further Familial Dysautonomia (FD) Research ROCKVILLE, Maryland. (August 10, 2015) – American Gene Technologies International, Inc. (AGT) today announced its receipt of an NIH Grant of $230,000 to further its Familial Dysautonomia (FD) research in 2015. Get the details below: NIH Grant Details

Biotech CEO Continues His Education In Order To Accomplish His Life Mission

By AGT | Jan 6, 2014
Filed Under:

Anyone who has experienced the death of a loved one from a terrible illness can appreciate the life mission of Mr. Jeff Galvin, CEO of American Gene Technologies (AGT). Armed with a bachelor’s degree in Economics from Harvard University, Jeff and AGT work to develop new technologies to find cures for many life-threatening diseases, including HIV and AIDS. Below, Jeff… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media

Send this to a friend